Abstract: Memantine is a drug approved for the treatment of moderate-to-severe Alzheimer's disease (AD), and there is ongoing research on the potential expansion of its clinical applicability. Published data on the pharmacokinetics of memantine in the mouse are still incomplete, particularly for chronic administration regimens and mouse models of specific genetic disorders. Down's syndrome (DS) is a genetic disorder known to affect multiple organs and systems, with the potential to alter significantly drug pharmacokinetics. Here, we describe a simple, efficient and sensitive GC/MS-based procedure for the determination of memantine concentrations in murine blood and tissue samples. We analysed pharmacokinetic properties of memantine, particularly its distribution in blood, brain and liver in the Ts65Dn mouse model of DS and euploid F1 hybrid mice after single intraperitoneal administrations of increasing doses of this drug. We also determined steady-state memantine concentrations in plasma, brain and liver after chronic oral administration of this drug in adult male Ts65Dn mice, euploid littermate controls and nursing or pregnant Ts65Dn mice. Our results revalidated the acute dose of memantine used in previously published work, determined the appropriate amount of memantine to be mixed into mouse chow to achieve steady and pharmacologically relevant plasma and tissue levels of this drug and demonstrated that memantine can be transferred from mother to offspring via maternal milk and placenta. Most of these findings are potentially applicable not only to the study of DS but also to other neurodevelopmental and neurodegenerative disorders.
Memantine (3,5-dimethyladamantan-1-amine) has been widely prescribed for the symptomatic treatment of patients with moderate-to-severe Alzheimer's disease (AD) since its approval in the European Union in 2002 and in the United States in 2003 [1] [2] [3] . To date, memantine is still one of only a handful of drugs approved for the treatment of AD. Its mechanism of action is generally thought to involve the uncompetitive, low-to-moderate affinity antagonism of N-methyl-D-aspartate (NMDA) receptors [1, 4] .
In addition to their putative role in AD, NMDA receptors are believed to play important roles in the pathogenesis of many other central nervous system diseases and disorders, such as Parkinson's disease, Huntington's disease, stroke, chronic pain, migraine, amyotrophic lateral sclerosis, multiple sclerosis and autism spectrum disorder [4] [5] [6] [7] [8] [9] [10] [11] . Therefore, over the past couple of decades, memantine has been investigated as a potential therapeutic agent for all these diseases and disorders. However, it should be noted that because memantine also binds to a number of other receptors, a few alternative mechanisms of action have been proposed. For example, recently, Moriguchi et al. [12] proposed that ATP-sensitive K + (K ATP ) channels are potentially relevant targets for memantine action in the treatment of AD. Our research team is particularly interested in the potential involvement of NMDA receptors and the therapeutic use of memantine in Down's syndrome (DS), which is a complex and variable set of phenotypes caused by the trisomy of chromosome 21 [13, 14] . Based on behavioural and electrophysiological data from mouse models of DS, we suggested that NMDA receptor dysfunction may play significant pathogenic roles in both the neurodevelopmental and the neurodegenerative components of DS [15] . These preclinical data also led to the design of a pilot clinical trial of memantine aiming at enhancing the cognitive abilities of individuals with DS [16] . Due to its small sample size, however, this pilot study was expectedly inconclusive. Still, post hoc power analysis of the resulting data was encouraging enough to lead to the design of a Phase II, follow-up clinical trial of memantine in adolescents and young adults with DS ('NCT02304302' at http:// www.clinicaltrials.gov).
From the neurodegenerative side of the equation, a Phase II study called 'Memantine for Dementia in Adults Older than 40 years with Down's Syndrome' (or, MEADOWS trial) failed to demonstrate memantine's efficacy in improving daily living skills or counteracting maladaptive behaviours in older adults with DS, many of who were already displaying signs and symptoms of dementia [17] . Among the potential reasons for the negative result of this particular trial, the low dose of memantine used and the typical argument about the likely futility of treating a neurodegenerative disorder after the damage being already done have been invoked [18] .
Given that our version of the glutamatergic hypothesis for DS [15] involves the presence of lifelong NMDA receptor dysfunction in persons with DS, we are particularly interested in the assessment of the long-term safety and efficacy of this drug in all phases of neurodevelopment, from the foetal stage into adulthood, including old age. Therefore, we developed a simple, efficient and sensitive procedure for the determination of memantine concentration in murine blood and tissues by simple extraction, followed by one-step derivatization and gas chromatography-mass spectrometry (GC/MS) analyses. We then applied this procedure to the analysis of the pharmacokinetic properties of memantine in blood, brain and liver in Ts65Dn and euploid F1 hybrid mice after acute, single-dose intraperitoneal (i.p.) administration of increasing doses of memantine. Finally, we determined the steady-state concentrations of memantine in plasma, brain and liver after chronic oral administration of this drug in adult male Ts65Dn mice, as well as in nursing and pregnant female Ts65Dn mice, that were fed with especially formulated mouse chow containing memantine. These procedures provided us with critical information on whether (and how much) memantine can be transferred from mothers to their offspring via maternal milk and placenta.
Materials and Methods
Animals. Ts65Dn mice were generated by repeated backcrossing of Ts65Dn females with B6EiC3SnF1/J hybrid males (C57BL/6JEiJ femalesC3H/HeSnJ males) in the Animal Resource Center (ARC) at Case Western Reserve University (CWRU). Ts65Dn and euploid F1 hybrid colonies were maintained in a 12:12-hr light/dark cycle (lights off at 6:00 p.m.). Water and food were given ad libitum. Ts65Dn mice were genotyped by polymerase chain reaction (PCR) as described by Duchon et al. [19] . Thirty-five Ts65Dn and 35 euploid F1 adult male mice (8-12 weeks) were used for acute and chronic memantine pharmacokinetic experiments. Three Ts65Dn and three euploid littermate control nursing female mice (8-12 weeks), as well as 3 Ts65Dn and three euploid littermate control timed-pregnant female mice (8-12 weeks), along with their litters, were used for chronic memantine pharmacokinetic experiments. All experimental methods were performed according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health) and were approved by the Institutional Animal Care and Use Committee (IACUC) at CWRU.
Drug treatments. For acute memantine treatments, saline solutions of memantine hydrochloride (kindly donated to ACSC by the Forest Research Institute, Inc., Commack, NY, USA) were administered i.p. to Ts65Dn and euploid B6EiC3HF1 male mice as individual single doses of 0, 2.5, 5.0, 10, 20 and 40 mg/kg in a volume of 6.25 ml/kg (five animals per dose for both genotypes). Blood, brain and liver samples were collected 15 min. after memantine administration. In addition, memantine was combined with NIH31 formula mouse diet (1816417-103, TestDiet, St. Louis, MO, USA) and administered orally at the doses of 100 mg/kg, 300 mg/kg and 500 mg/kg of food for chronic memantine treatment.
To assess the steady-state concentration of memantine in adult mice, five Ts65Dn and five euploid B6EiC3HF1 male mice were singly housed and fed ad libitum with memantine experimental food at a dose of 100 mg/kg of mouse chow. Blood, brain and liver samples were collected 24 hr after the beginning of the experiment, which occurred between 10:00 and 11:00 a.m. (i.e. 4-5 hr after the lights went on in the animal facility). Each adult mouse (regardless of genotype) consumed between 4.5 and 5 g of chow in a 24-hr interval.
We then investigated the steady-state concentration of memantine nursing female mice and their offspring after a two-dose chronic memantine regimen, and the potential transference of memantine from mother to offspring via maternal milk. To this end, three Ts65Dn and three euploid littermate control nursing female mice, along with their litters, were singly housed and fed ad libitum with memantine experimental food at 500 mg/kg of mouse chow for 7 days (P12-P18). Then, memantine experimental food at a dose of 300 mg/kg of chow was given ad libitum from P18 to P21. Blood, brain and liver samples were collected from all pups and nursing female mice, as well as milk samples from the dams.
Finally, three Ts65Dn and three euploid littermate control timedpregnant female mice were fed ad libitum with memantine experimental food in a dose of 500 mg/kg of mouse chow, beginning at 16 days after fertilization (E16). At day E18, prenatal pups were surgically removed from the uterus. Both pregnant and nursing females consumed between 10 and 12 g of chow in a 24-hr period.
Sample collection. Adult male mice were anaesthetized with 20% urethane (Sigma-Aldrich, St. Louis, MO, USA) dissolved in phosphate-buffered saline (PBS) by intraperitoneal injection (6.25 ml/ kg). Fifty to 100 ll of blood was collected by orbital venous plexus bleeding. Animals were then killed by cervical dislocation, and their brain and liver were collected.
Nursing female mice and their litters were separated for approximately 15 min. prior to milking. Single i.p. injections of oxytocin (4 U/kg body-weight) were administered to the dam in order to stimulate the release of milk. Fifteen minutes later, the dams were anaesthetized with 20% urethane in PBS by i.p. injection (6.25 ml/kg). Manual massage was applied around the mammary glands to stimulate milk ejection and drops of milk from each teat were collected using a Pasteur pipet [20] . After milking, blood was collected by orbital venous plexus bleeding. Then, the dams were killed by cervical dislocation and brain and liver were collected. Mouse pups were killed by rapid decapitation, and trunk blood, brain and liver were collected.
Finally, timed-pregnant female mice were anaesthetized under deep halothane (~1 ml) (Sigma-Aldrich) and then killed by decapitation. Next, prenatal pups were also killed by rapid decapitation and their brains were collected.
Determination of memantine concentration in blood and tissues. Briefly, memantine/amantadine were extracted by the addition of 100 ll of ammonium acetate (0.5 M) and 500 ll of methanol to 50 ll of blood and/or milk samples, and 3 ml of methanol was added to brain and liver samples (~20 mg). Samples were then homogenized and centrifuged. After centrifugation (11,884 g, 4°C, 15 min.), the supernatants were transferred to 12 9 75 mm glass tubes and evaporated to dryness. Dried samples were reconstituted in 1 ml of 100% ethanol, and 50 ll of amantadine hydrochloride, as the internal standard, was added to each sample (2.5 lg/ml) (Sigma-Aldrich). After centrifugation (11,884 g, 4°C, 15 min.), supernatants were transferred to GC/MS vials and evaporated to dryness. Finally, samples were resuspended in standard derivatization solution consisting of 50 ll of pyridine and 50 ll of N,O-bis(trimethylsilyl) acetamide) + 10% trimethylchlorosilane (BSA/TMCS), at 70°C for 40 min., and analysed by GC/MS. Standard curves were constructed using amantadine hydrochloride (as an internal standard) in varying amounts (0-10 lmol/l).
GC/MS analysis. Concentrations of memantine were determined using an Agilent 5973N-MSD equipped with an Agilent 6890 GC system (GC/MS). A DB17-MS capillary column (30 m 9 0.25 mm 9 0.25 lm) was used in all assays with a helium flow of 1 ml/min. Gas chromatography was as follows, samples were injected in splitless mode, injection held at 270°C, oven temperature started at 100°C held for 1 min., then ramp 10°C/min. until 300°C and held 4 min. isothermally. Total run time was 25 min. Detector was held at 300°C isothermally. Samples were analysed in SIM (selected ion monitoring) mode using electron impact ionization (EI). Ion dwell time was set to 10 msec. Retention times for memantine (m/z 194) and amantadine (m/z 166) were~10.60 min. and 10.75 min., respectively.
Statistical analysis. The results are presented as mean AE S.E.M. Measured mean values of memantine concentration in various samples (dependent variable) were compared by two-way analysis of variance (ANOVA) (Statistica, version 12, Dell Inc., Tulsa, OK, USA), which was followed, when appropriate, by a post hoc analysis by Fisher's least significant difference (LSD). The categorical factors were genotype and sample type. When comparing measurement means from two groups of samples, statistical significance was assessed using twotailed unpaired t-tests. Memantine calibration curves were analysed by simple linear regression models, and comparisons between the plasma, brain and liver distribution after acute administrations of memantine between euploid F1 hybrid and Ts65Dn mice were performed by straight-line, nonlinear regression fit of the data followed by the extra sum-of-squares F test algorithm in GraphPad Prism, version 7.02 (GraphPad Software Inc., La Jolla, CA, USA). For all statistical tests, a p-value of <0.05 was selected as the criterion for statistical significance. In the figures, statistically significant differences between group means were expressed as * and ***, for p < 0.05 and p < 0.001, respectively.
Results
Mass spectra of amantadine and memantine are illustrated in fig. 1A , B. For amantadine and memantine, m/z 166 and m/z 194 were monitored, respectively. Fig. 1C shows memantine's calibration curve in standard derivatization solution, which demonstrates a linear relationship between increasing amounts of memantine and measured ratio of memantine and a fixed quantity of amantadine (R 2 = 0.999). Using this method, the lowest detectable concentration of memantine was 0.05 lmol/ l. Although we have also generated standard curves in derivatized tissues, such as brain and liver tissues from Ts65Dn and euploid F1 wild-type mice, these curves were identical to the ones produced in standard derivatization solution within the limits of detection ( Figure S1 ). Therefore, for simplicity, we used the calibration curve displayed in fig. 1C as the single standard to calculate all memantine concentrations described in the present study. We quantified plasma, brain and liver concentrations of memantine in Ts65Dn and euploid F1, wild-type mice 15 min. after i.p. injections of progressively higher doses of this drug. We chose the 15-min. time-point to match the time interval used by Costa et al. [21] , in which our research team demonstrated that acute memantine i.p. injections of 5 mg/kg memantine selectively enhanced the behavioural performance of Ts65Dn mice in a fear conditioning test. Similar to previously published work in which memantine was injected subcutaneously (s.c.) in wild-type mice [22] , concentrations of memantine in plasma, brain and liver displayed a dose-dependent linear growth ( fig. 2) . We found that plasma concentrations of memantine 15 min. after a 5 mg/kg i.p. injection of memantine were 1.6 and 1.8 lmol/l for euploid F1, wild-type and Ts65Dn mice, respectively. A single slope was sufficient to describe properly the dose dependence of the measured memantine concentrations in both plasma (y Ts65Dn = 0.335x + 0.029, and y F1 = 0.335x -0.010, shared R 2 = 0. at least at high doses, memantine tends to concentrate more in the brain tissue of Ts65Dn mice than in the brains of euploid F1 mice after an acute injection of this drug. In mice of both genotypes, memantine levels in brain and liver tissues were %7 and %37 times higher than plasma levels, respectively. We also determined the steady-state concentrations of memantine in plasma, brain and liver from adult male euploid F1 and Ts65Dn mice, after 24-hr chronic oral administration of 100 mg of this drug mixed in 1 kg of mouse chow. Results from these experiments are depicted in fig. 3 . Two-way ANOVA showed that both genotype (F(1,24) = 6.178, p = 0.0203) and sample type (F(2,24) = 66.047, p < 0.0001) had significant effects on the measured steady-state concentration of memantine. Fisher PLSD post hoc tests, however, only detected a significant difference between the concentration of memantine in Ts65Dn and euploid F1 mice for brain tissue (p = 0.0331). The calculated p-values for the genotype dependence of memantine concentrations in plasma and liver were 0.8526 and 0.0757, respectively.
To establish a dosing regimen capable of producing stable memantine plasma concentrations in mouse pups from P12 (before eye opening) to P21 (weaning age), we performed several preliminary experiments (data not shown) in which we determined by trial and error that at least three oral doses of memantine were necessary. Firstly, we found that 500 mg of memantine per 1 kg of mouse chow was necessary from P12 to P18, so enough memantine was available in the milk to reach therapeutically relevant plasma levels (between 0.5 and 1 lM). Then, we found that from P18 until P21 (because the pups already started to nibble on mouse chow at the bottom of the cage), a dose of 300 mg/kg of chow was sufficient to maintain the same plasma levels. Finally, at P21, 100 mg of this drug mixed in 1 kg of mouse chow was sufficient to maintain pharmacologically relevant plasma levels of memantine in these pups after weaning.
Results of experiments in which three Ts65Dn and three euploid littermate control nursing female mice, along with their litters, were exposed to treatment with this two-dose chronic memantine regimen are depicted in fig. 4 . At P21, blood, brain, liver and milk samples were collected from all nursing female mice ( fig. 4A) , and blood, brain and liver samples were collected from the pups ( fig. 4B ). For the samples extracted from the nursing female mice, two-way ANOVA showed that sample type (F(3,16) = 16.086, p < 0.0001), but not genotype (F(1,16) = 0.036, p = 0.8521), had a significant effect on the measured steady-state concentration of memantine. In these nursing mice, the mean memantine concentration in milk (%8 lM) was found to be approximately 2.6 times higher than the plasma memantine concentration (%3 lM), whereas memantine levels in brain and liver tissues were %10 and %28 times higher than plasma levels, respectively. In contrast, for the samples extracted from the pups, two-way ANOVA calculations revealed that both genotype (F(1,59) = 29.988, p < 0.0001) and sample type (F(2,59) = 45.598, p < 0.0001) had significant effects on the measured steady-state concentrations of memantine. Post hoc tests identified significant difference between the memantine levels between pups from Ts65Dn mothers (n = 7) and euploid mothers (n = 15) for brain (p = 0.0001) and liver (p < 0.0001) tissue, but no significant difference in mean plasma concentrations of memantine was detected (p = 0.7139).
Finally, we investigated whether memantine was transferred from mother to offspring via placenta. Fig. 5 shows the mean memantine levels in pregnant mice ( fig. 5A ) and their foetuses ( fig. 5B ) after 48-hr oral treatment with memantine (500 mg/ kg of chow). Again, for the samples extracted from the pregnant mice, two-way ANOVA showed that sample source (F (2,12) = 19.157, p = 0.0002), but not genotype (F (1,12) = 0.791, p = 0.3917), had a significant effect on the measured steady-state concentration of memantine. However, for the samples extracted from the foetuses, we observed that both genotype (F(1, 68) = 8.501, p = 0.0048) and sample origin (F(1,68) = 94.310, p < 0.0001) had significant effects on the measured steady-state concentration of memantine. Post hoc tests identified significant difference between the memantine levels in placentas from Ts65Dn mothers (n = 14) and euploid mothers (n = 24) (p = 0.0003), but no significant difference was detected between the memantine levels in brains of the foetuses of Ts65Dn mothers (n = 13) and those of euploid mothers (n = 23) (p = 0.7193).
Discussion
In the present study, we described a simple, efficient and sensitive GC/MS-based, one-step derivatization procedure for the determination of memantine concentrations in murine blood and tissue samples. We used this procedure to analyse the pharmacokinetic properties of memantine in blood, brain and liver in the Ts65Dn and euploid F1 hybrid mice after single intraperitoneal administrations of increasing doses of this drug. Then, we determined steady-state memantine concentrations in plasma, brain and liver after chronic oral administration of this drug in adult male Ts65Dn mice, and in nursing or pregnant Ts65Dn mice. In these experiments, we revalidated the acute dose of memantine we had used in our previously published work, discovered the appropriate amount of memantine to be mixed into mouse chow to achieve steady and pharmacologically relevant plasma and tissue levels of this drug and learned that in the mouse, memantine can be transferred from mother to offspring via maternal milk and placenta.
There have been a few published methods for the determination of the concentration of memantine in blood and tissues [22] [23] [24] [25] [26] [27] [28] [29] . Based on these published reports and our expertise, we developed a unique procedure for measuring memantine concentration in blood and tissues using commonly found GC/MS. Using this new procedure, we were able to detect concentrations of memantine as low as 0.05 lmol/l, which is a level of sensitivity comparable to those described previously. To extract neutral amines (such as memantine/amantadine) efficiently from tissues and blood, we chose to use methanolic extraction with the addition of ammonium acetate to maintain alkalinity. For GC/MS analyses, memantine and amantadine were derivatized by the addition of a trimethylsilyl group, a common derivatization agent for many compounds. We demonstrated a strong linear response of memantine in murine blood and tissues. Additionally, the sensitivity of our method allowed us to discern a deviation in the response of memantine in the brains of Ts65Dn mice compared with control animals. The method described here employs a commonly used, versatile and sensitive derivatization procedure, coupled with electron impact GC/MS analyses, without cumbersome and lengthy HPLC purification, complex LC-MS/MS analyses or complex derivatization strategies coupled with chemical ionization mass spectrometry. Indeed, we found this methodology to be so straightforward and dependable that we are planning to use it to analyse memantine samples from our clinical studies.
We have shown that the memantine distribution in plasma, brain and liver of Ts65Dn and euploid F1 hybrid mice in response to single i.p., acute administrations of increasing doses of this drug (2.5-40 mg/kg) follows a simple linear dose dependence. This is in agreement with previously reported work in which memantine was injected s.c. to wild-type C57CL/6 mice [22] . In that study, these authors observed that 10 mg/kg memantine s.c. produced a mean plasma concentration of 2.15 lmol/l 100 min. after the injection. Given that most drugs reach peak concentration faster after i.p. injections than after s.c. injections, this result agrees well with our observation that a 10 mg/kg i.p. injection of memantine results in a mean plasma concentration of 3.27 lmol/l after a 15-min. delay. Also, because typical daily oral doses of 20 mg used in the treatment of AD lead to steady-state plasma concentrations of memantine ranging from 0.5 to 1 lmol/l, our findings confirm that a 10 mg/kg injection produces memantine plasma levels that are well above typical therapeutic values. In contrast, 15 min. after an i.p. injection, 2.5 and 5 mg/kg memantine produced plasma concentrations of 0.80 and 1.71 lmol/l, respectively, which means that these lower doses are more in line with therapeutically relevant levels of this drug.
One consistent, albeit unexpected, finding about the acute distribution of memantine in brain tissue was that, at doses equal or higher than 20 mg/kg i.p., memantine concentrates more in the brain tissue of Ts65Dn mice when compared with euploid, wild-type F1 mice. Although we are searching actively for a causal explanation for this phenomenon in our laboratories, it is also important to notice that at doses equal or below 10 mg/kg, the measured brain concentration of memantine in this mouse model of DS is indistinguishable from what was measured in the brains of F1 mice.
We also found that the chronic oral administration of memantine mixed in mouse chow, at a dose of 100 mg/kg of food, produced a reasonably stable plasma concentration of 0.5 lmol/l, which is consistent with therapeutically relevant doses of this drug. In contrast to our observation for acute i.p. dosing of memantine, we observed that chronic oral administration of this drug produced a lower concentration of memantine in the brains of Ts65Dn mice compared with wild-type, euploid F1 mice. Again, our research teams are currently investigating the reason(s) for this difference. Our working hypothesis is that because Ts65Dn mice have smaller body sizes and weights than euploid F1 mice, acutely injected memantine may take a shorter amount of time to penetrate Ts65Dn brain tissue compared with the brain of F1 mice. However, during chronic oral administration of memantine, enough time takes place for all body compartments to equilibrate. Under these circumstances, the relative brain concentrations of memantine should be determined primarily by genotype-dependent differences in tissue composition and/ or differences in the number or affinity of drug binding sites specific to the brain tissue compartment. This is the first study involving chronic oral administration of memantine mixed into the mouse chow. Adding test compounds into standard mouse feeding can be an effective, accurate and convenient means of chronically dosing animals for research purposes. In previous studies in a transgenic mouse model of AD [27] and in Ts65Dn mice [30] , memantine was administered orally in drinking water. More recently, Lee et al. [26] demonstrated that stable and clinically relevant doses of memantine could be achieved in rats by multiple gavage administrations of memantine dissolved in water. Simply administering memantine in drinking water poses several , were fed ad libitum with memantine experimental food at 500 mg/kg of mouse chow from P12 to P18. Then, memantine experimental food at a dose of 300 mg/kg of chow was given ad libitum from P18 to P21. Significant differences in memantine levels between pups from Ts65Dn mothers (n = 7) and euploid mothers (n = 15) were detected for brain (p = 0.0001) and liver (p < 0.0001) tissues (B). In each graph, the bars represent the mean AE S.E.M. and ***p < 0.001. were surgically removed from the uterus. No significant differences in the levels of memantine were detected between the pregnant Ts65Dn and euploid control mice. However, a significant difference in memantine levels was found between placentas removed from Ts65Dn mothers (n = 14) and euploid mothers (n = 24) (p = 0.0003) (B). In each graph, the bars represent the mean AE S.E.M. and ***p < 0.001. potential issues. Firstly, significant amounts of water (and consequently drug) can be wasted from leaky water bottles or even during physiological drinking by rodents. Secondly, given that memantine possesses a bitter taste, the addition of this drug to drinking water might change the water consumption habits by the animal being tested. Thirdly, solid food is generally absorbed more slowly than water by the gastrointestinal system, which should produce a slower and more stable absorption of memantine when mixed with mouse chow versus drinking water. Regarding the administration of memantine via gavage, this technique may work well in rats and certain strains of mice, however, as shown in previous work by Stasko and Costa [31] , Ts65Dn mice are especially susceptible to gavage-induced stress, which can be a significant confounder in the interpretation of the results of certain behavioural tests involving these animals. It is not unlikely that the same may be true for other mouse models of neurodevelopmental and neurodegenerative disorders.
It is important to note that when we examined both nursing and pregnant female mice, also exposed to a chronic oral regimen of memantine (figs 4A and 5A), we did not detect any genotype-dependent differences in the concentrations of memantine in plasma, brain or liver. Here, any difference in memantine brain concentration might have been erased because of the longer period of treatment, or because they were nursing female mice as opposed to male mice, or yet because the control female mice used in these experiments were euploid littermate mice born from Ts65Dn mothers, and not wild-type, euploid F1 hybrid mice. (The main reason for using euploid F1 hybrid male in the first two experiments was simply to produce generalizable data that may prove valuable for future studies by groups interested in the study of memantine in mouse models of diseases or disorders other than DS, whereas the experiments with nursing and pregnant female mice were targeted specifically to studies in DS.)
A noteworthy finding from the experiments involving nursing female mice was the fact that we measured significant amounts of memantine in the milk from both nursing Ts65Dn and euploid control mothers. No significant genotype-dependent difference was found in the actual concentrations of memantine measured. However, what makes this piece of data truly novel is that to our knowledge, this is the first experimental demonstration of the excretion of memantine in breast milk. Because of the moderate lipophilicity of this drug, this possibility had been entertained in the past [32] but never experimentally confirmed.
In these experiments, we also observed that pups nursing from Ts65Dn female mice that were exposed to chronic memantine treatment displayed consistently lower levels of this drug in brain and liver tissue compared with pups from euploid control mice. Although the statistical analysis did not expose genotype-dependent differences in memantine plasma levels in these pups, the simple inspection of fig. 4B suggests this may be an artefact of the use of multivariate ANOVA post hoc comparisons applied to subgroups for which mean values were quite different. If instead, we perform a simple t-test comparison between the memantine plasma concentrations in pups nursing from Ts65Dn versus euploid control mothers, we find a significantly lower plasma level of this drug in pups nursing from Ts65Dn mothers (1.15 AE 0.37 lmol/l, n = 7) compared with pups nursing from euploid mothers (3.02 AE 0.28 lmol/l, n = 15; p < 0.001). These consistently lower levels of memantine across tissues has led us to speculate that perhaps Ts65Dn mothers may not be as efficient in nursing their pups as the euploid control mothers. It was also interesting to notice that there was no significant genotype-dependent difference in memantine brain levels in foetuses from pregnant Ts65Dn and euploid control female mice exposed to chronic memantine treatment. This happened in spite of the fact that the placentas from pregnant Ts65Dn mice concentrated significantly more memantine than those from pregnant euploid control female mice.
The observations of efficient transference of memantine from blood to milk and from placenta to foetus are quite important to us, because they provide us with a convenient way to administer this drug in various stages of mouse development, which is particularly important for the study of such a quintessential developmental disorder such as DS. With small adjustments, these findings should also be applicable to the study of the effects of memantine in mouse models of other neurodevelopmental disorders.
Finally, from the perspective of human pharmacotherapy, given the approved application of memantine, at present, it is very unlikely that a nursing or pregnant woman will receive memantine treatment. As the field of clinical indications of this drug expands into disorders such as autism and migraine, however, we may soon encounter scenarios in which the knowledge of efficient transference of memantine from blood to milk and from placenta to foetus in animal models will prove important in the risk evaluation of treatment continuation in pregnant or nursing women.
The analytical methods and some of the results described here should find important applications not only to the study of DS, but also to the investigation of many other neurodevelopmental and neurodegenerative disorders for which the use of memantine as a potential therapeutic agent is being considered and/or actively investigated.
